Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
COVID-19 vaccines target emerging variants, offering improved protection. Learn about their effectiveness, timing, and safety ...
Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...
A government advisory committee has canceled a meeting on flu shot recommendations, raising concerns amid shifts in ...
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.